Shri Ganesh Associates Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 18.85%
(FY 2023)
- Profit 625.23%
(FY 2023)
- Ebitda 564.35%
(FY 2023)
- Net Worth 24.99%
(FY 2023)
- Total Assets 6.59%
(FY 2023)
About Shri Ganesh Associates Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ranganathan Kannan, Gopalachari Kannan, and Kannan Parthasarathy serve as directors at the Company.
- CIN/LLPIN
U51397TN2010PTC075882
- Company No.
075882
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 May 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shri Ganesh Associates Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gopalachari Kannan  | Managing Director | 31-May-2010 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ranganathan Kannan | Director | 31-May-2010 | Current |
| Kannan Parthasarathy | Director | 31-May-2010 | Current |
Financial Performance of Shri Ganesh Associates Pharmaceuticals.
Shri Ganesh Associates Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.85% increase. The company also saw a substantial improvement in profitability, with a 625.23% increase in profit. The company's net worth Soared by an impressive increase of 24.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shri Ganesh Associates Pharmaceuticals?
In 2023, Shri Ganesh Associates Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Truzen Lifesciences Private LimitedActive 5 years 2 monthsRanganathan Kannan and Gopalachari Kannan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shri Ganesh Associates Pharmaceuticals?
Unlock and access historical data on people associated with Shri Ganesh Associates Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shri Ganesh Associates Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shri Ganesh Associates Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
